Olendalizumab

Names

[ CAS No. ]:
2210314-30-8

[ Name ]:
Olendalizumab

Biological Activity

[Description]:

Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Immunology/Inflammation >> Complement System

[Target]

Complement protein C5a[1]


[In Vitro]

Olendalizumab 可用作生物素化捕获试剂，在 Bioaffy wash 1 中的工作浓度为 100 μg/mL，同时 AlexaFluor 标记的抗 C5a 克隆 2942 在 Rexxip F 中的工作浓度为 4 μg/mL[1]。 补体系统的成员，如 C3、C5a、C5b-9，包括受体，如 C3aR 和 C5aR，介导病毒感染后的肺损伤。 此外，C5/C5a 更是冠状病毒引起的肺损伤中的非沉默补体。Olendalizumab 是有效的 C5a 抑制剂[2]。

[References]

[1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106.  

[2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.